GLP-1 Weight Loss Drugs Work Similarly Across Age, Sex, Race, and Starting Weight
A large meta-analysis found GLP-1 receptor agonists produce consistent weight loss regardless of patient age, sex, race/ethnicity, starting BMI, or baseline HbA1c.
Quick Facts
What This Study Found
GLP-1 receptor agonists showed consistent weight loss efficacy across patient subgroups defined by age, sex, race/ethnicity, baseline BMI, and baseline HbA1c.
Key Numbers
How They Did This
Systematic review and meta-analysis of randomized controlled trials from MEDLINE, Embase, and Cochrane, analyzing heterogeneity of treatment effects across patient subgroups.
Why This Research Matters
Confirming that GLP-1 RAs work consistently across diverse populations means clinicians can prescribe them confidently without worrying about reduced efficacy in certain patient groups.
The Bigger Picture
As GLP-1 RAs become first-line obesity treatments, confirming equitable efficacy across demographics is essential for health equity and broad clinical adoption.
What This Study Doesn't Tell Us
Subgroup analyses from trials may have limited power to detect small differences; real-world populations may differ from clinical trial participants.
Questions This Raises
- ?Do these consistent effects hold in longer-term real-world use beyond trial durations?
- ?Are there genetic or metabolic factors not captured by demographics that predict differential response?
Trust & Context
- Key Stat:
- Consistent across all subgroups No significant heterogeneity of treatment effects by age, sex, race, BMI, or HbA1c
- Evidence Grade:
- Systematic review and meta-analysis of RCTs — the highest level of evidence synthesis, though limited by the quality and diversity of included trials.
- Study Age:
- Published 2026 in JAMA Internal Medicine. Reflects the latest available trial data.
- Original Title:
- Heterogeneity of Treatment Effects of Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss in Adults: A Systematic Review and Meta-Analysis.
- Published In:
- JAMA internal medicine (2026)
- Authors:
- Alexander, G Caleb(3), Xiao, Xuya(2), Dilek, Sophie, Lewis, Sydney, Deng, Qilin, Kim, Minji, Bolanle, Dami, Saldanha, Ian J, Mehta, Hemalkumar B
- Database ID:
- RPEP-14737
Evidence Hierarchy
Frequently Asked Questions
Do GLP-1 drugs work better for some people than others?
This meta-analysis found that GLP-1 receptor agonists produce similar weight loss regardless of age, sex, race, starting weight, or diabetes control, suggesting broadly consistent efficacy.
Which GLP-1 drugs were included in this analysis?
The study analyzed semaglutide, liraglutide, exenatide, lixisenatide, and dulaglutide across multiple randomized controlled trials.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-14737APA
Alexander, G Caleb; Xiao, Xuya; Dilek, Sophie; Lewis, Sydney; Deng, Qilin; Kim, Minji; Bolanle, Dami; Saldanha, Ian J; Mehta, Hemalkumar B. (2026). Heterogeneity of Treatment Effects of Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss in Adults: A Systematic Review and Meta-Analysis.. JAMA internal medicine. https://doi.org/10.1001/jamainternmed.2025.8222
MLA
Alexander, G Caleb, et al. "Heterogeneity of Treatment Effects of Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss in Adults: A Systematic Review and Meta-Analysis.." JAMA internal medicine, 2026. https://doi.org/10.1001/jamainternmed.2025.8222
RethinkPeptides
RethinkPeptides Research Database. "Heterogeneity of Treatment Effects of Glucagon-Like Peptide-..." RPEP-14737. Retrieved from https://rethinkpeptides.com/research/alexander-2026-heterogeneity-of-treatment-effects
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.